Dasatinib and Nilotinib Similarly Efficacious for CML in Chronic Phase

Share this content:
Dasatinib and nilotinib show no significant difference in treatment efficacy for treatment-naive patients with chronic myeloid leukemia in chronic phase.
Dasatinib and nilotinib show no significant difference in treatment efficacy for treatment-naive patients with chronic myeloid leukemia in chronic phase.

Dasatinib and nilotinib show no significant difference in treatment efficacy for treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP), according to a study published in Cancer.1

In previous randomized trials, efficacy of dasatinib and nilotinib were separately compared to that of imatinib, though the former 2 were not compared directly. The researchers of the present study evaluated dasatinib against nilotinib via propensity score, in which data from patients on parallel phase 2 trials for either drug were analyzed.

Eighty-seven patients from each trial were matched via propensity scoring; all clinically-relevant responses and survival rates were similar between the 2 groups.

RELATED: Half of Patients in Remission 11 Months After Nilotinib Discontinuation

The authors conclude that nilotinib and dasatinib are similarly efficacious for patients with CML-CP, and both are equally recommended as a first-line therapy.

Reference

  1. Takahashi K, Kantarjian HM, Yang Y, et al. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 2016 Aug 10. doi: 10.1002/cncr.30197 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs